[Pancytopenia associated with thioguanine use]

Area of Science:

• Pharmacogenomics
• Gastroenterology

Background:

• Thiopurine drugs (azathioprine, mercaptopurine, thioguanine) are mainstays in treating inflammatory bowel disease (IBD).
• These medications carry risks, including serious bone marrow toxicity.
• Awareness of potential adverse effects is crucial for patient safety.

Observation:

• A 56-year-old male with ulcerative colitis experienced leukopenia while on mercaptopurine.
• Following initiation of thioguanine ten months later, he developed life-threatening pancytopenia.
• TPMT genotyping revealed the patient was a poor metabolizer (TPMT3A*/3A*).

Findings:

• The patient's genetic makeup (TPMT3A*/3A*) predisposed him to severe toxicity from thioguanine.
• Reduced thiopurine methyltransferase activity significantly increases the risk of adverse drug reactions.
• This severe outcome was potentially preventable with appropriate precautions.

Implications:

• TPMT genotyping should be considered before initiating thiopurine therapy in IBD patients.
• Dose adjustments based on TPMT activity are essential for managing thiopurine drugs safely.
• Personalized medicine approaches, guided by pharmacogenomics, can mitigate severe adverse drug events in IBD treatment.